These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3322253)

  • 1. Mechanisms underlying the antimotion sickness effects of psychostimulants.
    Kohl RL; Lewis MR
    Aviat Space Environ Med; 1987 Dec; 58(12):1215-8. PubMed ID: 3322253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug effectiveness on experimental optokinetic and vestibular motion sickness.
    Brandt T; Dichgans J; Wagner W
    Aerosp Med; 1974 Nov; 45(11):1291-7. PubMed ID: 4611183
    [No Abstract]   [Full Text] [Related]  

  • 5. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons.
    Geracitano R; Federici M; Bernardi G; Mercuri NB
    Ann N Y Acad Sci; 2006 Aug; 1074():320-9. PubMed ID: 17105928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural mechanisms of motion sickness.
    Takeda N; Morita M; Horii A; Nishiike S; Kitahara T; Uno A
    J Med Invest; 2001 Feb; 48(1-2):44-59. PubMed ID: 11286016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the mechanism of antimotion sickness effects of mexidol].
    Motin VG; Iasnetsov VV
    Aviakosm Ekolog Med; 2010; 44(1):64-6. PubMed ID: 20804002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prokinetic effects of erythromycin after antimotion sickness drugs.
    Stewart JJ; Wood MJ; Parish RC; Wood CD
    J Clin Pharmacol; 2000 Apr; 40(4):347-53. PubMed ID: 10761161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action.
    Jaju BP; Wang SC
    J Pharmacol Exp Ther; 1971 Mar; 176(3):718-24. PubMed ID: 4329456
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
    Kennedy RE; Wood CD; Graybiel A; McDonough RB
    Aerosp Med; 1966 Apr; 37(4):408-11. PubMed ID: 5954449
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of severe motion sickness with antimotion sickness drug injections.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central aspects of drugs for motion sickness and vertigo.
    McCabe BF
    Adv Otorhinolaryngol; 1973; 20():458-69. PubMed ID: 4575761
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of antimotion sickness drugs: a new effective remedy revealed.
    Wood CD; Graybiel A
    Aerosp Med; 1970 Aug; 41(8):932-3. PubMed ID: 4988606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.